Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.
about
KNOW-KT (KoreaN cohort study for outcome in patients with kidney transplantation: a 9-year longitudinal cohort study): study rationale and methodologyEffect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective studyOptimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study.Chronic progressive calcineurin nephrotoxicity: an overstated concept.Challenges and considerations in diagnosing the kidney disease in deteriorating graft function.A case of late kidney allograft failure: a clinical pathological conference from American Society of Nephrology Kidney Week 2011.Validation of tacrolimus equation to predict troughs using genetic and clinical factors.Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotypeGenetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Cryptic B cell response to renal transplantation.Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF GenomicsEarly Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study.IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES.Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Clinical role of the renal transplant biopsy.Is it time to give up with calcineurin inhibitors in kidney transplantation?Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.Through a glass darkly: seeking clarity in preventing late kidney transplant failureConversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection.Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.Inhibition of WISE preserves renal allograft function.Glomerular damage as a predictor of renal allograft loss.Chronic calcineurin inhibitor nephrotoxicity-lest we forget.Long-term outcomes following sirolimus conversion after renal transplantation.Late graft failure after kidney transplantation as the consequence of late versus early events.Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
P2860
Q33617623-12419929-8EFF-4872-B8A1-C93E1E0CF8C2Q33879559-287B97D2-F00F-4F10-A46D-C77066221120Q35210278-ECFC5851-56AA-44A1-A562-4699F0CFD6D4Q35929301-61C3B485-E711-458B-80F4-6C3ED557FA6EQ36365811-0080F25A-C11E-4713-A810-F8018AA371FAQ36371094-636CEB37-6565-4221-B848-8EC7B26C4810Q36630077-3160B66D-A0CF-4DF9-8C9C-9B8C9CF71C31Q36824123-67DD8F19-342A-44C1-9F9E-9A69A3759794Q37013588-6BDCF608-B38B-46C7-9EB4-505E0BF77FE0Q37150424-D207FF78-A991-44BC-860C-2A9C4A3463FDQ37209745-4B0F127B-58AC-4844-B2B4-01662AFB5EB8Q37346593-6D8AD1F1-423E-4CB2-AC2E-663052F621B5Q37563822-39DD219E-60F2-42B5-B2B1-EF60086A3418Q37660263-024A2036-E365-412E-BEE2-BE801BF6C477Q37974480-D8A78273-554B-4C9C-991F-4615A2762AB3Q38156847-AFD8178A-B1B1-4B82-852C-AFF2C8769344Q38230449-C63EE8EC-FF3E-43DB-A2C1-51E6AEB1D12FQ38237365-1806DDCF-EAD6-4ECF-B51D-DDAD9871D1B6Q38241710-6D3EC0A4-0DFE-4DCB-94C8-DE6560DBE95AQ38569092-9F95CA51-286E-4717-85B1-66050ACAA017Q39207543-6FD23A9A-EFB9-49E7-98A1-0304872A9370Q40149564-8181CE85-888C-4413-B5AC-60A53F199F02Q42045071-E865F6C9-7F9A-4CE3-B5FB-E44E241C23BCQ43065199-4FD9A3A0-3C78-4AE1-97C8-996504EB556DQ43759235-C73BC5BB-F435-4353-89E5-3A1E74217071Q44544352-F40E7D76-038A-4093-8E3E-D1EEE32EDF49Q50005462-726D0109-EAB5-4CEF-BB94-38FD4E9E05CFQ51262438-EB80EA12-5DBF-4011-A842-ED073DB6EC3C
P2860
Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@ast
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@en
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@nl
type
label
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@ast
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@en
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@nl
prefLabel
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@ast
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@en
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@nl
P2093
P1476
Histopathologic clusters diffe ...... ary data from the DeKAF study.
@en
P2093
L Hunsicker
P304
P356
10.1111/J.1600-6143.2009.02943.X
P407
P577
2009-12-23T00:00:00Z